Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
Rectify Pharmaceuticals is taking an approach to disease that led to a successful franchise of Vertex Pharmaceutical lung drugs and expanding it to more diseases in more organs in the body. The startup has launched with $100 million in financing.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Check out the latest news from HealthMine, Vital, Cleerly Health and more.
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
The biotech venture capital firm said it plans to invest the money into existing portfolio companies. Several other VC firms have also announced new funds in the last several months.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Deals worth $50 million or more are becoming more frequent, even in Series A. But a VC investor said underlying drivers in life sciences are different from the technology sector.
The company, which cut 300 neuroscience R&D jobs in January, is making the funding a centerpiece of its $600 million VC boost.
Atlas and Third Rock Ventures have co-led a $48.5 million Series A for Magenta, a Boston start-up hoping to revive the stem cell field with its novel transplant platform.
The biotech markets have softened. What's the state of the forthcoming biotech IPO? Atlas Venture's Bruce Booth weighs in.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Atlas Venture just closed its tenth fund at $280 million – marking its switch over to a biotech-only firm, the firm’s Bruce Booth blogged today. “At our core, we’re biotech therapeutics startup folks, and that’s where we’re going to focus,” he wrote. Conversely the company’s last fund, at $265 million in 2013, was split between […]
There are some distinct parallels between the World Cup and the biotech biz, or so says Bruce Booth of Atlas Venture in an entertaining but spot-on recent blog post. As we enter the frenzied final days of the international soccer tournament, we’d be well-served to hang onto some lessons learned from the sport (before America forgets about […]
Scientists suspect there’s a connection between many common neurodegenerative diseases and malfunctioning lysosomes, or processing centers in human cells that break down proteins and eliminate debris. Now a new company called Lysosomal Therapeutics is tapping into the relationship between the two to discover and develop new treatments for rare diseases and common neurodegenerative diseases, starting […]
Overcoming challenges posed by the growing number of infections that are resistant to traditional antibiotics is the goal of a startup surfacing today with a $3 million Series A and a drug development partnership with Roche. Spero Therapeutics was born last year out of a collaboration between VC firm Atlas Venture’s seed program and Partners […]
A biotech startup formed by Atlas Venture is collaborating with Biogen Idec to develop a treatment for inherited forms of Ataxia– a degenerative neurological condition that leads to physical disabilities, according to a company statement. They include the loss of coordination of hands, fingers, arms, legs but it can also cause a curvature of the […]